Molecular analysis of lymphoid malignancies

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Lymphoid malignancies are extensively studied at the molecular level.
• Simultaneous investigation of t(14;18) translocation, B-cell clonality, and bcl2 gene expression in lymphoid malignancies has not been previously reported.
• Understanding these molecular markers is crucial for diagnosing and treating lymphoid cancers.

Purpose of the Study:

• To investigate the simultaneous occurrence of t(14;18) chromosomal translocation, B-cell clonality, and bcl2 gene expression in lymphoid malignancies.
• To determine the prevalence of these molecular abnormalities in a cohort of patients.
• To explore the potential role of bcl2 overexpression as an independent marker.

Main Methods:

• Polymerase Chain Reaction (PCR) was used to detect t(14;18) translocation and assess B-cell clonality.
• Western blotting was employed for semi-quantitative analysis of bcl2 gene expression.
• A cohort of 41 patients with lymphoid malignancies was analyzed.

Main Results:

• The t(14;18) translocation was detected in 25% of patients, with a higher prevalence (47%) in centrofollicular lymphoma.
• BCL2 was overexpressed in 84% of evaluable patients.
• B-cell monoclonality was observed in 57% of B-cell neoplasia patients, irrespective of t(14;18) status.
• BCL2 overexpression was the sole detected abnormality in 4 patients.

Conclusions:

• BCL2 overexpression is a frequent molecular event in lymphoid malignancies, often occurring independently of the t(14;18) translocation.
• The findings highlight the significance of BCL2 in lymphoid cancers.
• Further research is warranted to ascertain if bcl2 expression levels can predict chemotherapy response.